Recent Developments in Drug | 合法醫療器材資訊網

Thesurfaceoftheseballoonscarryantiproliferativedrugssuchaspaclitaxelorsirolimusthatisdeliveredtothevesselwallwheninflated.Thedrughelpsprevent ...

Drug-coated balloons (DCB)[1], also referred to as drug-eluting balloons (DEB), were created as a way to reduce very high restenosis rates in peripheral vessels. They also have been investigated in clinical trials to prevent coronary artery in-stent restenosis. 

The surface of these balloons carry antiproliferative drugs such as paclitaxel or sirolimus that is delivered to the vessel wall when inflated. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs are now approved in the U.S. Food and Drug Administration (FDA) clearance for the treatment of peripheral artery disease (PAD) in the legs and hyperplasia in arteriovenous (AV) access fistulae in dialysis patients. DCBs also are used outside the U.S. to treat in-stent restenosis due to scar tissue proliferation inside st...